Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Viral Vector Manufacturing Market to Grow Substantially by 2029- Brandessence Market Research

This image opens in the lightbox

News provided by

Brandessence Market Research and Consulting Private Limited

14 Sep, 2023, 14:49 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Sept. 14, 2023 /PRNewswire/ -- According to a comprehensive research report by Brandessence Market Research (BMRC), "Viral Vector Manufacturing Market Size, Share Outlook Growth By Top Company, Development, Application, Segmentations, Trends And Forecast 2021-2029."


Viral vectors are genetically modified viruses generally used by biologists to administer genetic materials into living cells. These vectors act as vehicles to transport the desired genetic payload into specific cells, allowing the introduction of new genetic material or the correction of faulty genes within the cells. The manufacturing process of these vectors involve vector design, cell culture, transduction or transfection, viral vector amplification, purification, quality control, followed by formulation and storage.

The business intelligence report curated by Brandessence Market Research aims at empowering industry participants with an extensive overview of this marketplace. It offers detailed insights into the key growth drivers, restraints, opportunities, and challenges, that are shaping the profit trajectory of this industry vertical. A scrutiny of the listed segments and geographical landscape is entailed in this report. It further contains a country-wise breakdown of each region with detailed insights on their revenue streams, opportunities, and future projections, just to name a few. The report enumerates the key players operating in the market. It sheds light into the product portfolio, market positioning, strategies, revenue, pricing trends, and other crucial aspects associated with each player.         

Key takeaways:

  • Growing prevalence of chronic and infectious diseases along with the rapidly evolving medical research infrastructure are aiding market expansion.
  • By type, the adeno-associated viral vectors segment is poised to amass notable gains due to the increased adoption of these vectors in gene therapy.
  • MEA is projected to capture a substantial revenue share owing to the increased prevalence of genetic disorders and growing cognizance about the benefits offered by viral vectors.

Viral Vector Manufacturing Market Report Scope:

Report Metric

Details

Base Year

2021

Study Period

2022-2029

Key Players/Companies

Sanofi, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Merck KGaA, Lonza, Oxford BioMedica, GENERAL ELECTRIC COMPANY, uniQure N.V., Spark Therapeutics, Inc., Brammer Bio, FinVector Vision Therapies, Cobra Biologics, Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., REGENXBIO Inc. and Others

Get Free Sample PDF Brochure:

https://brandessenceresearch.com/downloadSample/PostId/666

Viral Vector Manufacturing Market is projected to amplify with a substantial CAGR over the analysis timeline of 2022-2029.

Elaborating the key trends and dynamics of Viral Vector Manufacturing Market:

Growing prevalence of chronic and infectious diseases along with the rapidly evolving medical research infrastructure are the primary factors aiding the expansion of this business vertical. Alongside, increased healthcare expenditure, growing R&D activities in the field, along with surge in the geriatric population base are creating lucrative opportunities for this marketspace to prosper. Moreover, escalating demand for vaccines and growing focus on preventive healthcare are adding momentum to the progression of this industry sphere.

Major growth drivers:

Increased occurrence of genetic disorders- There has been a surging pervasiveness of genetic disorders across the globe. It is worth noting that gene therapies work wonder in treating disorders such as certain types of cancer, muscular dystrophy, and inherited condition. Gene therapies typically involve the use of viral vectors which in turn is stimulating the overall dynamics of this business vertical.

Rise in biotechnology funding- Government and private organizations are making heaving investments to enhance the biotechnology vertical of their respective nations. This influx of funding has resulted in an expansion of manufacturing facilities and improved technologies for viral vector production. These factors are creating an upward trend in this industry sphere.

Challenges:

Regulatory challenges- The regulatory landscape for gene therapies and viral vectors is quite stern. Companies operating in this industry need to navigate through complex and evolving regulations set by different health authorities. Maintaining compliance with these regulations, especially in different regions, requires a deep understanding of regulatory requirements and effective communication with regulatory agencies. This is hindering the remuneration scope of this market space.

Competitive landscape of Viral Vector Manufacturing Market:

  • Sanofi
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Merck KGaA
  • Lonza
  • Oxford BioMedica
  • GENERAL ELECTRIC COMPANY
  • uniQure N.V.
  • Spark Therapeutics, Inc.
  • Brammer Bio
  • FinVector Vision Therapies
  • Cobra Biologics
  • Cell and Gene Therapy Catapult
  • Kaneka Eurogentec S.A.
  • REGENXBIO Inc.
  • Others

Browse In-depth Market Research Report (300 Pages) on Viral Vector Manufacturing Market:

https://brandessenceresearch.com/healthcare/viral-vector-manufacturing-market-size

Segmental Assessment:

By type, the adeno-associated viral vectors segment is poised to amass notable gains over 2022-2029. This is due to the increased adoption of these vectors in gene therapy.

Based on disease, the cancer segment is expected to garner significant returns over the stipulated timeline. This is ascribed to the growing cancer prevalence and elevating demand for advanced therapeutics like gene therapy for cancer treatment.

Geographical analysis & landscape:

Middle East & Africa Viral Vector Manufacturing Market:

MEA is projected to capture a substantial revenue share over the analysis timeline. This is attributable to the increased prevalence of genetic disorders, growing cognizance about the benefits offered by viral vectors, along with rising healthcare expenditure. Moreover, surging number of clinical trials coupled with increased R&D activities in the field are fuelling the growth of this regional industry.

Europe:

Europe has emerged as one of the fastest growing regions in this market space.  This is credited to the growing occurrence of chronic diseases like cancer, surge in the geriatric population base, and the booming biotechnology sector. Alongside, influx of advanced technologies in the vertical and the presence of prominent players are expediting the expansion of this business sphere.

Opportunities in this industry:

Surge in the geriatric populace- The aging population is high susceptible to a wide range of diseases including cancer, genetic disorder, along with other chronic and infectious diseases. With age, our bodies undergo numerous changes which in turn exposes us to the risk of such disorders. Medications, vaccines, and therapies involving viral vectors are typically adopted for the treatment of the target diseases among the geriatric individuals. A steep rise in the volume of elderly populace is positively swaying the dynamics of this market.

Major developments in Viral Vector Manufacturing Market:

Acquisitions:

In May 2020, Charles River Laboratories, a global provider of research services to the biopharmaceutical industry, acquired Vigene Biosciences, a viral vector CDMO.

Porter's Five Forces Analysis:

Threat of New Entrants: The threat of new entrants in the viral vector manufacturing market can be relatively low due to several factors. Establishing a viral vector manufacturing facility requires significant capital investment, specialized equipment, and technical expertise. Moreover, the industry is heavily regulated, and obtaining the necessary approvals and certifications can be time-consuming and costly. Established companies also benefit from economies of scale and established relationships with biotech and pharmaceutical clients. However, the growing demand for viral vectors and the potential for high profitability might attract some new entrants, especially if they bring innovative technologies or strategic partnerships.

Purchase Copy of This Research Report @: https://brandessenceresearch.com/Checkout?report_id=666

Bargaining Power of Buyers: 

The bargaining power of buyers, such as biotech and pharmaceutical companies, can be moderate to high. Viral vectors are a crucial component in gene therapies and other advanced treatments, making them essential for the success of these companies' products. However, the viral vector manufacturing market has several players, providing buyers with options and competitive pricing. The differentiation of viral vector products, technological advancements, and the overall quality of services offered can influence the bargaining power of buyers.

Bargaining Power of Suppliers: 

The bargaining power of suppliers to viral vector manufacturers can vary. Suppliers of raw materials, specialized equipment, and components used in the manufacturing process may have some power, especially if they provide unique or critical inputs. However, the viral vector manufacturing industry is likely to have multiple suppliers for many of these inputs, which reduces the supplier's bargaining power. Additionally, as the industry grows, manufacturers might invest in developing in-house production of critical components, further reducing supplier power.

Threat of Substitutes: 

The threat of substitutes in the viral vector manufacturing market can be relatively low. Viral vectors play a unique and essential role in gene therapies and other advanced biologics. While there may be alternative gene delivery technologies under development, such as non-viral vectors, viral vectors remain the primary choice due to their efficiency and ability to deliver genes to target cells effectively.

Competitive Rivalry: 

The competitive rivalry in the viral vector manufacturing market can be moderate to high. The market has witnessed the entry of several players, including contract development and manufacturing organizations (CDMOs) and large biotech companies. Competition is driven by factors like technology expertise, manufacturing capacity, regulatory compliance, and the ability to meet client demands. Differentiated services, product quality, and strong client relationships are essential for companies to gain a competitive edge.

Related Blogs:

Predictive Analytics Powered by AI: Unlocking Insights for the Future of Healthcare

Natural Language Processing (NLP) in Healthcare: Unlocking the Potential

Posluma: A Targeted Oncology Breakthrough in Prostate Cancer Imaging

Fezolinetant by Veozah: Advancing Women's Health by Astellas Pharma Inc.

A Hopeful Sign for Migraine Sufferers: Zavzpret

Rethinking Treatment Options for a Better Future with Hemophilia Gene Therapy

Personalized Medicine Driven By AI is revolutionizing healthcare

By Lexicon Pharmaceuticals, Inpefa endorsed by the FDA

Innoviva Specialty Therapeutics' Xacduro Will Facilitate the Treatment of Bacterial Pneumonia

Xdemvy: Lotilaner as a Revolutionary Demodex Blepharitis Treatment

Pegunigalsidase Alfa-IWXJ, Elfabrio's Active Ingredient, May Help Cure Fabry Disease

A Successful Drug Launch's Roadmap

Your Partner in Closing Gaps, Increasing Competitiveness, and Making a Global Impact: Enabling Investor Excellence

Managing the Challenges in the Immunotherapy World

Managing the Alzheimer's Landscape: How We Point Market Participants in the Direction of Special Solutions

The Future of Skin-Credible Care Is Unlocked by New Topical Drug Delivery Therapies, Creating a Psoriasis Care Crisis!

Levodopa/Carbidopa's New Formulation ND0612 Performs Effectively in Phase III Trials: A Victory Against Parkinson's Disease

About Us:

Brandessence Market Research & Consulting Pvt ltd.

Brandessence Market Research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Follow Us: LinkedIn

Contact: 
Mr. Vishal Sawant 
Email: vishal@brandessenceresearch.com
Email: Sales@brandessenceresearch.com
Corporate Sales: +44-2038074155 
Asia Office: +917447409162

Logo: https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg 

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.